Protagenic Therapeutics Ownership
| PTIX Stock | USD 0.73 0.08 12.31% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 4 M | Current Value 5 M | Avarage Shares Outstanding 4.6 M | Quarterly Volatility 4.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Protagenic |
Protagenic Stock Ownership Analysis
About 14.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.27. Protagenic Therapeutics last dividend was issued on the 27th of July 2016. The entity had 1:4 split on the 23rd of March 2023. Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. To find out more about Protagenic Therapeutics contact the company at 212 994 8200 or learn more at https://www.protagenic.com.Besides selling stocks to institutional investors, Protagenic Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Protagenic Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Protagenic Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Protagenic Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 14.0% of Protagenic Therapeutics are currently held by insiders. Unlike Protagenic Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Protagenic Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Protagenic Therapeutics' insider trades
Protagenic Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Protagenic Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Protagenic Therapeutics backward and forwards among themselves. Protagenic Therapeutics' institutional investor refers to the entity that pools money to purchase Protagenic Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Eagle Asset Management, Inc. | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 40.9 K | Vanguard Group Inc | 2024-09-30 | 33.2 K | Susquehanna International Group, Llp | 2024-06-30 | 26.6 K | Geode Capital Management, Llc | 2024-09-30 | 26.1 K | Advisor Group Holdings, Inc. | 2024-06-30 | 21.4 K | Fny Investment Advisers, Llc | 2024-06-30 | 18.8 K | State Street Corp | 2024-06-30 | 13.8 K | Ubs Group Ag | 2024-06-30 | 10.1 K | Tower Research Capital Llc | 2024-06-30 | 6.8 K |
Protagenic Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protagenic Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protagenic Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protagenic Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Protagenic Therapeutics Outstanding Bonds
Protagenic Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protagenic Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protagenic bonds can be classified according to their maturity, which is the date when Protagenic Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| PL 1618 15 APR 26 Corp BondUS74368CBC73 | View | |
| US74368CAX20 Corp BondUS74368CAX20 | View | |
| US743674BE29 Corp BondUS743674BE29 | View | |
| US74368CAY03 Corp BondUS74368CAY03 | View | |
| PRXNA 3832 08 FEB 51 Corp BondUS74365PAE88 | View | |
| PL 5366 06 JAN 26 Corp BondUS74368CBQ69 | View | |
| PRXNA 4027 03 AUG 50 Corp BondUS74365PAD06 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.